Summary of Key Points
Novartis recently invested $1.9 billion (a upfront payment of $105 million plus up to an additional $1.8 billion) to collaborate with Antares Corporation on the development of small molecule therapies for difficult-to-treat tumor targets. This move essentially represents a “resignation” on Novartis’ part: they acknowledge that they have fallen behind in the PI3Kα (a common mutation target in cancer) research area due to a wrong technical approach, missing out on better opportunities. Now, they are forced to spend money to acquire external expertise in order to catch up.
Detailed Analysis
1. Why Did Novartis’ PI3Kα Drugs Fail?
In 2019, Novartis launched Piqray, the world’s first PI3Kα inhibitor, which was a milestone for the industry. PI3Kα mutations are present in 30-40% of HR+ breast cancer patients, giving Novartis a significant market advantage. However, Piqray had a fatal flaw: it could not distinguish between “bad proteins” (mutated PI3Kα) and “good proteins” (wild-type). This meant that the drug, while inhibiting tumor growth, also interfered with normal cell glucose metabolism, causing serious side effects such as high blood sugar, rashes, and diarrhea in patients. Moreover, Piqray could not be used in combination with Novartis’ own CDK4/6 inhibitors, a commonly used combination for breast cancer treatment, significantly reducing its commercial value. Later, Roche’s new drug Itovebi was approved, stealing Novartis’ market share.
2. The Competitor’s Secret Weapon: How Powerful Is the Technology to Identify “Hidden Pockets”?
While Novartis was struggling with these side effects, a smaller company called Scorpion used advanced technology to change the game. Their approach, known as chemical proteomics, allows them to scan protein-complex interactions in living cells and identify “hidden pockets” (allosteric sites) that traditional methods cannot detect. These sites are not located in the active center of PI3Kα but function like switches; binding to these sites can alter the protein’s structure, inhibiting only the mutated form without affecting the wild-type. Based on this technology, Scorpion developed STX-478, an oral drug that can cross the blood-brain barrier and has shown promising clinical results (23% response rate in breast cancer and 44% in gynecological tumors), with no high blood sugar side effects even in diabetic patients. This solution perfectly addressed Novartis’ problems.
3. Why Did Novartis Lag Behind?
Novartis missed two critical opportunities: In January 2025, Eli Lilly acquired Scorpion’s STX-478 project for $2.5 billion without Novartis making a move. After Scorpion was split into Antares, Novartis waited a year before partnering, allowing Eli Lilly to take the lead with this mature asset. This hesitation may have been due to Novartis’ confidence in their own capabilities or an underestimation of Scorpion’s technology, resulting in them watching as their competitor developed the next-generation drug.
4. The $1.9 Billion “Resignation”: What Three Things Does Novartis Acknowledge?
This deal is a public admission of failure by Novartis:
- The Failure of Piqray: Their drug’s side effects were too severe, and it could not compete with the new generation of products. Therefore, they acquired another company’s PI3Kα project for $3 billion three months ago and are now investing an additional $1.9 billion in Antares to address this weakness.
- Missing Out on Opportunities: They had the chance to acquire Scorpion two years ago but did not, and now they are paying a high price for Antaris’ technology, coming late to the game.
- Inability to Tackle Difficult-to-Treat Targets: Novartis executives stated that they “need Antares to unlock new therapies,” implying that their own efforts were insufficient. The collaboration is structured so that Antares leads the research, with Novartis funding but without direct involvement, as a precaution against another wrong decision.
5. Industry Insights: Is Choosing the Right Technical Path More Important than Hard Work?
Novartis did not lack effort; Piqray was a groundbreaking product, but their choice of “orthostatic inhibition” (directly blocking the active center) meant they could not distinguish between mutated and wild-type proteins. Scorpion’s approach of “allosteric inhibition,” which targets hidden sites to alter protein structure, opened up new possibilities. This highlights that in the biopharmaceutical industry, the right direction is more crucial than sheer effort. Novartis’ $1.9 billion investment buys not just a drug but also a belated entry ticket into the new era of allosteric inhibition, as well as a recognition of their past mistakes.
Conclusion
Novartis’ $1.9 billion deal is both a acknowledgment of past failures and a bet on the future. It serves as a reminder that in technology-driven industries, missing a technological revolution can result in significant financial losses to catch up. For everyone, whether in the workplace or entrepreneurship, choosing the right path and method is often more decisive than sheer effort.